The global neovascular age-related macular degeneration treatment market is expected to garner a market value of US$ 3 billion in 2023 and is expected to accumulate a market value of US$ 4.89 billion by registering a CAGR of 5% in the forecast period 2023 to 2033. The market for neovascular age-related macular degeneration treatment registered a CAGR of 3.5% in the historical period 2018 to 2022.
The Neovascular Age-related Macular Degeneration Treatment market is a segment of the healthcare industry that deals with the effective management of the condition. The market is expected to grow significantly in the coming years due to the increasing prevalence of the condition worldwide. Neovascular age-related macular degeneration is a serious eye condition that affects older adults and can lead to vision loss. The treatment of nAMD typically involves medications that are injected into the eye to stop the growth of abnormal blood vessels in the retina. These medications are known as anti-VEGF drugs.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | US$ 3 billion |
| Anticipated Forecast Value (2033) | US$ 4.89 billion |
| Projected Growth Rate (2023 to 2033) | 5% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider, Future Market Insights- the market for Neovascular Age-related Macular Degeneration Treatment reflected a value of 3.5% during the historical period, 2018 to 2022.
The neovascular age-related macular degeneration treatment market has been growing rapidly in recent years due to the increasing prevalence of nAMD and the availability of effective drugs for its treatment. The market is expected to continue growing in the coming years as the aging population continues to grow.
The key players in the neovascular age-related macular degeneration treatment market include pharmaceutical companies such as Roche, Novartis, Regeneron, and Bayer. These companies are investing heavily in research and development to bring new and improved drugs to market for the treatment of nAMD. In addition to anti-VEGF drugs, other treatments for nAMD are also being developed, including gene therapy and sustained-release drug delivery systems. These new treatments have the potential to improve patient outcomes and reduce the need for frequent injections.
Moreover, strategic collaborations, mergers and acquisitions, and product innovations are expected to further drive the growth of the Neovascular Age-related Macular Degeneration Treatment market. Key players in the market are investing in R&D activities to develop new treatment options and improve the efficacy of existing ones. The market offers growth opportunities for pharmaceutical companies, medical device manufacturers, and healthcare providers. Overall, the market for neovascular age-related macular degeneration treatment is expected to register a CAGR of 5% in the forecast period 2023 to 2033.
Growing Awareness along with increasing prevalence of Focal Segmental Glomerulosclerosis (FSGS) to drive growth
The neovascular age-related macular degeneration (nAMD) treatment market has been experiencing significant growth in recent years and is expected to continue growing in the coming years. Several factors are driving this growth, including:
Principal Consultant
Expensive Cost of Treatment to restrict Market Growth
The cost of nAMD treatment with anti-VEGF drugs can be very high, and this can limit patient access to these treatments. Some patients may not be able to afford the cost of treatment, while others may face limitations in their insurance coverage.
Moreover, Anti-VEGF drugs are typically administered through injections directly into the eye, which can be uncomfortable and inconvenient for patients. Additionally, these injections need to be given on a regular basis, which can be challenging for patients who have difficulty traveling to clinics or for those who may be homebound.
Increasing awareness and diagnosis of the condition Shaping Landscape in South & East Asia
The neovascular age-related macular degeneration (nAMD) treatment market is turning out to be promising in the South & East Asia region. The prevalence of nAMD is increasing in the region due to aging populations, changing lifestyles, and increasing prevalence of diabetes.
Several pharmaceutical companies have been focusing on expanding their market presence in the region by investing in research and development, strategic partnerships, and collaborations. For example, Novartis and Roche have been leading players in the nAMD treatment market in the region, and have been expanding their product portfolios and conducting clinical trials for new treatments.
In addition, the availability of biosimilars of anti-VEGF drugs has increased in the region, which has made treatment more affordable for patients. The use of biosimilars has also increased competition in the market, leading to more affordable treatment options. However, challenges remain in the region, including limited access to specialized ophthalmologists, inadequate healthcare infrastructure in some areas, and low awareness of nAMD and its treatment options among patients and healthcare providers.
Overall, the nAMD treatment market in South & East Asia is expected to continue growing in the coming years, driven by factors such as increasing patient awareness, expanding healthcare infrastructure, and the introduction of new treatments.
Increasing Focus on technological advancements driving demand for Neovascular Age-related Macular Degeneration Treatment in North America
The aging population in North America is contributing to the increasing prevalence of nAMD. According to the American Academy of Ophthalmology, more than 10 million Americans are affected by AMD, with nAMD accounting for a significant portion of these cases.
North America is at the forefront of research and development of new nAMD treatments, and the availability of advanced treatment options such as anti-VEGF drugs has contributed to the growth of the market. Additionally, the introduction of gene therapy and sustained-release drug delivery systems has further expanded treatment options.
The strong healthcare infrastructure in North America has contributed to the growth of the nAMD treatment market, with access to specialized ophthalmologists, well-equipped healthcare facilities, and advanced diagnostic and treatment technologies. The increasing awareness of nAMD and its treatment options among patients and healthcare providers has contributed to the growth of the market. Patients are now seeking earlier diagnosis and treatment, which has increased the demand for effective nAMD treatments.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Wet AMD segment to hold a significant share and push market growth
Wet AMD is likely to account for a significant share in the Neovascular Age-related Macular Degeneration Treatment market is Wet AMD. Wet AMD is a more severe form of the disease and can progress rapidly, causing severe vision loss or blindness if left untreated.
This has led to a higher demand for treatments that can effectively manage the condition, such as anti-vascular endothelial growth factor (anti-VEGF) drugs. These drugs are used to block the growth of abnormal blood vessels and reduce fluid leakage in the retina, slowing down the progression of the disease and improving vision.
Late-stage AMD segment to hold a significant share and push market growth
Among the different stages of AMD, the Late-stage AMD segment is likely to account for a significant share in the neovascular age-related macular degeneration treatment market.
Late-stage AMD includes both wet AMD and geographic atrophy, which are advanced forms of the disease that can cause severe vision loss or blindness if left untreated. As a result, there is a higher demand for effective treatments for late-stage AMD, such as anti-vascular endothelial growth factor (anti-VEGF) drugs, which can help slow down the progression of the disease and improve vision.
Key players in the market include companies such as Competition Deep Dive, Competition Deep Dive, Bausch & Lomb Incorporate, Novartis AG, Pfizer Inc., ALLERGAN, Acucela Inc., Santen Pharmaceuticals Co., Ophthotech Corporation, Alimera Sciences Inc.GlaxoSmithKline PLC, Regeneron Pharmaceutical Inc., Bayer AG, Rxi Pharmaceuticals Inc. along with healthcare providers and technology companies among other global players.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | US$ 3 billion |
| Market Value in 2033 | US$ 4.89 billion |
| Growth Rate | CAGR of 5% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in US$ Billion and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
The neovascular age-related macular degeneration treatment market size reaches US$ 3 billion in 2023.
The market is set to surge at a 5% CAGR, reaching a valuation of US$ 4.89 billion by 2033.
The market witnessed a 3.5% CAGR between 2018 and 2022.
The United States exhibits promising potential for neovascular age-related macular degeneration treatment due to its advanced healthcare infrastructure.
The Wet AMD segment demonstrates significant expansion in the neovascular age-related macular degeneration treatment market.
1. Executive Summary | Neovascular Age-related Macular Degeneration Treatment Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Drug Type, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Type, 2023 to 2033 5.3.1. Ranibizumab 5.3.2. Aflibercept 5.3.3. Bevacizumab 5.3.4. Brolucizumab 5.3.5. Faricimab 5.4. Y-o-Y Growth Trend Analysis By Drug Type, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Drug Type, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Disease Type 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Disease Type, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Disease Type, 2023 to 2033 6.3.1. Dry AMD 6.3.2. Wet AMD 6.4. Y-o-Y Growth Trend Analysis By Disease Type, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Disease Type, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Age Group 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By Age Group , 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Age Group , 2023 to 2033 7.3.1. Less Than 60 7.3.2. Between 60 to 80 7.3.3. More Than 80 7.4. Y-o-Y Growth Trend Analysis By Age Group , 2018 to 2022 7.5. Absolute $ Opportunity Analysis By Age Group , 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Gender 8.1. Introduction / Key Findings 8.2. Historical Market Size Value (US$ Million) Analysis By Gender, 2018 to 2022 8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Gender, 2023 to 2033 8.3.1. Male 8.3.2. Female 8.4. Y-o-Y Growth Trend Analysis By Gender, 2018 to 2022 8.5. Absolute $ Opportunity Analysis By Gender, 2023 to 2033 9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Stage of Disease 9.1. Introduction / Key Findings 9.2. Historical Market Size Value (US$ Million) Analysis By Stage of Disease, 2018 to 2022 9.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Stage of Disease, 2023 to 2033 9.3.1. Early-stage AMD 9.3.2. Intermediate AMD 9.3.3. Late-stage AMD 9.4. Y-o-Y Growth Trend Analysis By Stage of Disease, 2018 to 2022 9.5. Absolute $ Opportunity Analysis By Stage of Disease, 2023 to 2033 10. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 10.1. Introduction / Key Findings 10.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022 10.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033 10.3.1. Hospital Pharmacy 10.3.2. Specialty Pharmacy 10.3.3. Online Pharmacy 10.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022 10.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033 11. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 11.1. Introduction 11.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 11.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 11.3.1. North America 11.3.2. Latin America 11.3.3. Europe 11.3.4. South Asia 11.3.5. East Asia 11.3.6. Oceania 11.3.7. MEA 11.4. Market Attractiveness Analysis By Region 12. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. United States 12.2.1.2. Canada 12.2.2. By Drug Type 12.2.3. By Disease Type 12.2.4. By Age Group 12.2.5. By Gender 12.2.6. By Stage of Disease 12.2.7. By Distribution Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Drug Type 12.3.3. By Disease Type 12.3.4. By Age Group 12.3.5. By Gender 12.3.6. By Stage of Disease 12.3.7. By Distribution Channel 12.4. Key Takeaways 13. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. Brazil 13.2.1.2. Mexico 13.2.1.3. Rest of Latin America 13.2.2. By Drug Type 13.2.3. By Disease Type 13.2.4. By Age Group 13.2.5. By Gender 13.2.6. By Stage of Disease 13.2.7. By Distribution Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Drug Type 13.3.3. By Disease Type 13.3.4. By Age Group 13.3.5. By Gender 13.3.6. By Stage of Disease 13.3.7. By Distribution Channel 13.4. Key Takeaways 14. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. Germany 14.2.1.2. United Kingdom 14.2.1.3. France 14.2.1.4. Spain 14.2.1.5. Italy 14.2.1.6. Rest of Europe 14.2.2. By Drug Type 14.2.3. By Disease Type 14.2.4. By Age Group 14.2.5. By Gender 14.2.6. By Stage of Disease 14.2.7. By Distribution Channel 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Drug Type 14.3.3. By Disease Type 14.3.4. By Age Group 14.3.5. By Gender 14.3.6. By Stage of Disease 14.3.7. By Distribution Channel 14.4. Key Takeaways 15. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. India 15.2.1.2. Malaysia 15.2.1.3. Singapore 15.2.1.4. Thailand 15.2.1.5. Rest of South Asia 15.2.2. By Drug Type 15.2.3. By Disease Type 15.2.4. By Age Group 15.2.5. By Gender 15.2.6. By Stage of Disease 15.2.7. By Distribution Channel 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Drug Type 15.3.3. By Disease Type 15.3.4. By Age Group 15.3.5. By Gender 15.3.6. By Stage of Disease 15.3.7. By Distribution Channel 15.4. Key Takeaways 16. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 16.2.1. By Country 16.2.1.1. China 16.2.1.2. Japan 16.2.1.3. South Korea 16.2.2. By Drug Type 16.2.3. By Disease Type 16.2.4. By Age Group 16.2.5. By Gender 16.2.6. By Stage of Disease 16.2.7. By Distribution Channel 16.3. Market Attractiveness Analysis 16.3.1. By Country 16.3.2. By Drug Type 16.3.3. By Disease Type 16.3.4. By Age Group 16.3.5. By Gender 16.3.6. By Stage of Disease 16.3.7. By Distribution Channel 16.4. Key Takeaways 17. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 17.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 17.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 17.2.1. By Country 17.2.1.1. Australia 17.2.1.2. New Zealand 17.2.2. By Drug Type 17.2.3. By Disease Type 17.2.4. By Age Group 17.2.5. By Gender 17.2.6. By Stage of Disease 17.2.7. By Distribution Channel 17.3. Market Attractiveness Analysis 17.3.1. By Country 17.3.2. By Drug Type 17.3.3. By Disease Type 17.3.4. By Age Group 17.3.5. By Gender 17.3.6. By Stage of Disease 17.3.7. By Distribution Channel 17.4. Key Takeaways 18. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 18.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 18.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 18.2.1. By Country 18.2.1.1. GCC Countries 18.2.1.2. South Africa 18.2.1.3. Israel 18.2.1.4. Rest of MEA 18.2.2. By Drug Type 18.2.3. By Disease Type 18.2.4. By Age Group 18.2.5. By Gender 18.2.6. By Stage of Disease 18.2.7. By Distribution Channel 18.3. Market Attractiveness Analysis 18.3.1. By Country 18.3.2. By Drug Type 18.3.3. By Disease Type 18.3.4. By Age Group 18.3.5. By Gender 18.3.6. By Stage of Disease 18.3.7. By Distribution Channel 18.4. Key Takeaways 19. Key Countries Market Analysis 19.1. U.S. 19.1.1. Pricing Analysis 19.1.2. Market Share Analysis, 2022 19.1.2.1. By Drug Type 19.1.2.2. By Disease Type 19.1.2.3. By Age Group 19.1.2.4. By Gender 19.1.2.5. By Stage of Disease 19.1.2.6. By Distribution Channel 19.2. Canada 19.2.1. Pricing Analysis 19.2.2. Market Share Analysis, 2022 19.2.2.1. By Drug Type 19.2.2.2. By Disease Type 19.2.2.3. By Age Group 19.2.2.4. By Gender 19.2.2.5. By Stage of Disease 19.2.2.6. By Distribution Channel 19.3. Brazil 19.3.1. Pricing Analysis 19.3.2. Market Share Analysis, 2022 19.3.2.1. By Drug Type 19.3.2.2. By Disease Type 19.3.2.3. By Age Group 19.3.2.4. By Gender 19.3.2.5. By Stage of Disease 19.3.2.6. By Distribution Channel 19.4. Mexico 19.4.1. Pricing Analysis 19.4.2. Market Share Analysis, 2022 19.4.2.1. By Drug Type 19.4.2.2. By Disease Type 19.4.2.3. By Age Group 19.4.2.4. By Gender 19.4.2.5. By Stage of Disease 19.4.2.6. By Distribution Channel 19.5. Germany 19.5.1. Pricing Analysis 19.5.2. Market Share Analysis, 2022 19.5.2.1. By Drug Type 19.5.2.2. By Disease Type 19.5.2.3. By Age Group 19.5.2.4. By Gender 19.5.2.5. By Stage of Disease 19.5.2.6. By Distribution Channel 19.6. U.K. 19.6.1. Pricing Analysis 19.6.2. Market Share Analysis, 2022 19.6.2.1. By Drug Type 19.6.2.2. By Disease Type 19.6.2.3. By Age Group 19.6.2.4. By Gender 19.6.2.5. By Stage of Disease 19.6.2.6. By Distribution Channel 19.7. France 19.7.1. Pricing Analysis 19.7.2. Market Share Analysis, 2022 19.7.2.1. By Drug Type 19.7.2.2. By Disease Type 19.7.2.3. By Age Group 19.7.2.4. By Gender 19.7.2.5. By Stage of Disease 19.7.2.6. By Distribution Channel 19.8. Spain 19.8.1. Pricing Analysis 19.8.2. Market Share Analysis, 2022 19.8.2.1. By Drug Type 19.8.2.2. By Disease Type 19.8.2.3. By Age Group 19.8.2.4. By Gender 19.8.2.5. By Stage of Disease 19.8.2.6. By Distribution Channel 19.9. Italy 19.9.1. Pricing Analysis 19.9.2. Market Share Analysis, 2022 19.9.2.1. By Drug Type 19.9.2.2. By Disease Type 19.9.2.3. By Age Group 19.9.2.4. By Gender 19.9.2.5. By Stage of Disease 19.9.2.6. By Distribution Channel 19.10. India 19.10.1. Pricing Analysis 19.10.2. Market Share Analysis, 2022 19.10.2.1. By Drug Type 19.10.2.2. By Disease Type 19.10.2.3. By Age Group 19.10.2.4. By Gender 19.10.2.5. By Stage of Disease 19.10.2.6. By Distribution Channel 19.11. Malaysia 19.11.1. Pricing Analysis 19.11.2. Market Share Analysis, 2022 19.11.2.1. By Drug Type 19.11.2.2. By Disease Type 19.11.2.3. By Age Group 19.11.2.4. By Gender 19.11.2.5. By Stage of Disease 19.11.2.6. By Distribution Channel 19.12. Singapore 19.12.1. Pricing Analysis 19.12.2. Market Share Analysis, 2022 19.12.2.1. By Drug Type 19.12.2.2. By Disease Type 19.12.2.3. By Age Group 19.12.2.4. By Gender 19.12.2.5. By Stage of Disease 19.12.2.6. By Distribution Channel 19.13. Thailand 19.13.1. Pricing Analysis 19.13.2. Market Share Analysis, 2022 19.13.2.1. By Drug Type 19.13.2.2. By Disease Type 19.13.2.3. By Age Group 19.13.2.4. By Gender 19.13.2.5. By Stage of Disease 19.13.2.6. By Distribution Channel 19.14. China 19.14.1. Pricing Analysis 19.14.2. Market Share Analysis, 2022 19.14.2.1. By Drug Type 19.14.2.2. By Disease Type 19.14.2.3. By Age Group 19.14.2.4. By Gender 19.14.2.5. By Stage of Disease 19.14.2.6. By Distribution Channel 19.15. Japan 19.15.1. Pricing Analysis 19.15.2. Market Share Analysis, 2022 19.15.2.1. By Drug Type 19.15.2.2. By Disease Type 19.15.2.3. By Age Group 19.15.2.4. By Gender 19.15.2.5. By Stage of Disease 19.15.2.6. By Distribution Channel 19.16. South Korea 19.16.1. Pricing Analysis 19.16.2. Market Share Analysis, 2022 19.16.2.1. By Drug Type 19.16.2.2. By Disease Type 19.16.2.3. By Age Group 19.16.2.4. By Gender 19.16.2.5. By Stage of Disease 19.16.2.6. By Distribution Channel 19.17. Australia 19.17.1. Pricing Analysis 19.17.2. Market Share Analysis, 2022 19.17.2.1. By Drug Type 19.17.2.2. By Disease Type 19.17.2.3. By Age Group 19.17.2.4. By Gender 19.17.2.5. By Stage of Disease 19.17.2.6. By Distribution Channel 19.18. New Zealand 19.18.1. Pricing Analysis 19.18.2. Market Share Analysis, 2022 19.18.2.1. By Drug Type 19.18.2.2. By Disease Type 19.18.2.3. By Age Group 19.18.2.4. By Gender 19.18.2.5. By Stage of Disease 19.18.2.6. By Distribution Channel 19.19. GCC Countries 19.19.1. Pricing Analysis 19.19.2. Market Share Analysis, 2022 19.19.2.1. By Drug Type 19.19.2.2. By Disease Type 19.19.2.3. By Age Group 19.19.2.4. By Gender 19.19.2.5. By Stage of Disease 19.19.2.6. By Distribution Channel 19.20. South Africa 19.20.1. Pricing Analysis 19.20.2. Market Share Analysis, 2022 19.20.2.1. By Drug Type 19.20.2.2. By Disease Type 19.20.2.3. By Age Group 19.20.2.4. By Gender 19.20.2.5. By Stage of Disease 19.20.2.6. By Distribution Channel 19.21. Israel 19.21.1. Pricing Analysis 19.21.2. Market Share Analysis, 2022 19.21.2.1. By Drug Type 19.21.2.2. By Disease Type 19.21.2.3. By Age Group 19.21.2.4. By Gender 19.21.2.5. By Stage of Disease 19.21.2.6. By Distribution Channel 20. Market Structure Analysis 20.1. Competition Dashboard 20.2. Competition Benchmarking 20.3. Market Share Analysis of Top Players 20.3.1. By Regional 20.3.2. By Drug Type 20.3.3. By Disease Type 20.3.4. By Age Group 20.3.5. By Gender 20.3.6. By Stage of Disease 20.3.7. By Distribution Channel 21. Competition Analysis 21.1. Competition Deep Dive 21.1.1. F.Hoffmann-La Roche AG 21.1.1.1. Overview 21.1.1.2. Product Portfolio 21.1.1.3. Profitability by Market Segments 21.1.1.4. Sales Footprint 21.1.1.5. Strategy Overview 21.1.1.5.1. Marketing Strategy 21.1.2. Bausch + Lomb 21.1.2.1. Overview 21.1.2.2. Product Portfolio 21.1.2.3. Profitability by Market Segments 21.1.2.4. Sales Footprint 21.1.2.5. Strategy Overview 21.1.2.5.1. Marketing Strategy 21.1.3. Novartis AG 21.1.3.1. Overview 21.1.3.2. Product Portfolio 21.1.3.3. Profitability by Market Segments 21.1.3.4. Sales Footprint 21.1.3.5. Strategy Overview 21.1.3.5.1. Marketing Strategy 21.1.4. Pfizer Inc. 21.1.4.1. Overview 21.1.4.2. Product Portfolio 21.1.4.3. Profitability by Market Segments 21.1.4.4. Sales Footprint 21.1.4.5. Strategy Overview 21.1.4.5.1. Marketing Strategy 21.1.5. Allergan Plc. 21.1.5.1. Overview 21.1.5.2. Product Portfolio 21.1.5.3. Profitability by Market Segments 21.1.5.4. Sales Footprint 21.1.5.5. Strategy Overview 21.1.5.5.1. Marketing Strategy 21.1.6. Acucela Inc. 21.1.6.1. Overview 21.1.6.2. Product Portfolio 21.1.6.3. Profitability by Market Segments 21.1.6.4. Sales Footprint 21.1.6.5. Strategy Overview 21.1.6.5.1. Marketing Strategy 21.1.7. Santen Pharmaceuticals Co. 21.1.7.1. Overview 21.1.7.2. Product Portfolio 21.1.7.3. Profitability by Market Segments 21.1.7.4. Sales Footprint 21.1.7.5. Strategy Overview 21.1.7.5.1. Marketing Strategy 21.1.8. Ophthotech Corporation 21.1.8.1. Overview 21.1.8.2. Product Portfolio 21.1.8.3. Profitability by Market Segments 21.1.8.4. Sales Footprint 21.1.8.5. Strategy Overview 21.1.8.5.1. Marketing Strategy 21.1.9. Alimera Sciences Inc. 21.1.9.1. Overview 21.1.9.2. Product Portfolio 21.1.9.3. Profitability by Market Segments 21.1.9.4. Sales Footprint 21.1.9.5. Strategy Overview 21.1.9.5.1. Marketing Strategy 21.1.10. GSK plc. 21.1.10.1. Overview 21.1.10.2. Product Portfolio 21.1.10.3. Profitability by Market Segments 21.1.10.4. Sales Footprint 21.1.10.5. Strategy Overview 21.1.10.5.1. Marketing Strategy 21.1.11. Regeneron Pharmaceuticals Inc. 21.1.11.1. Overview 21.1.11.2. Product Portfolio 21.1.11.3. Profitability by Market Segments 21.1.11.4. Sales Footprint 21.1.11.5. Strategy Overview 21.1.11.5.1. Marketing Strategy 21.1.12. Bayer AG 21.1.12.1. Overview 21.1.12.2. Product Portfolio 21.1.12.3. Profitability by Market Segments 21.1.12.4. Sales Footprint 21.1.12.5. Strategy Overview 21.1.12.5.1. Marketing Strategy 21.1.13. RXi Pharmaceuticals Inc. 21.1.13.1. Overview 21.1.13.2. Product Portfolio 21.1.13.3. Profitability by Market Segments 21.1.13.4. Sales Footprint 21.1.13.5. Strategy Overview 21.1.13.5.1. Marketing Strategy 22. Assumptions & Acronyms Used 23. Research Methodology
Explore Healthcare Insights
View Reports
Neovascular Age-related Macular Degeneration Treatment Market
